Clinical characteristics. by Jesse A. Davidson (3158913)

13C5-adenosine production with ex vivo alkaline phosphatase supplementation. by Jesse A. Davidson (3158913)

Correlation of AP activity to 13C5-adenosine production pre-operation and prior to separation from cardiopulmonary bypass. by Jesse A. Davidson (3158913)

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine with CD73 inhibition. by Jesse A. Davidson (3158913)

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine without CD73 inhibition. by Jesse A. Davidson (3158913)

13C5-adenosine production without ectonucleotidase inhibition, with CD73 inhibition, and with alkaline phosphatase inhibition. by Jesse A. Davidson (3158913)

Adenosine production with AP supplementation + = significant at the 0.05 level adjusted for multiple comparisons. by Jesse A. Davidson (3158913)

Alkaline Phosphatase, Soluble Extracellular Adenine Nucleotides, and Adenosine Production after Infant Cardiopulmonary Bypass by Jesse A. Davidson (3158913)

“…Inhibition of alkaline phosphatase led to a marked decrease in 13C5-adenosine production (11.9μmol/L vs 2.7μmol/L; p<0.0001). …”

Ratio of 13C5-adenosine production with and without CD73 inhibition, pre-operation and prior to separation from cardiopulmonary bypass. by Jesse A. Davidson (3158913)

RNF5 depletion suppresses PEL xenograft tumor growth and decreases the levels of cell cycle gene expression and hedgehog signaling in tumors. by Xiaojuan Li (351842)

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

Muscle-specific knockdown of <i>nSMase</i> decreases a subset of ceramide species that are decreased in <i>Gba1b</i> mutants. by Kathryn A. Jewett (3756811)

Clinical characteristics of diabetic (DB) or normoglycemic (NG) women with obesity from the ABOS cohort at inclusion (M0) and 12 months after surgery (M12). by Marie Favennec (3165672)

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A by Rodrigo Velázquez-Moctezuma (3776023)

“…Culturing J6/JFH1_ΔHVR1 (genotype 2a), for which fitness was decreased by L665W, with AR5A generated AR5A-resistant viruses with the substitutions I345V, L665S, and S680T, which we introduced into J6/JFH1 and J6/JFH1_ΔHVR1. …”

Proposed model for vRNP assembly on Rab11a+ vesicles. by Julianna Han (9354280)

“…In the absence of Rab11a, vRNPs are scattered in the cytoplasm, decreasing the likelihood of association between the eight individual RNP segments, and ultimately resulting in the production of defective particles with misassembled genomes. …”

DNase I overexpression reduced <i>A3A</i> upregulation upon MeV infection. by Pierre Khalfi (7868252)

Design and Synthesis of Novel PET Radiotracers for Imaging Sphingosine-1-Phosphate Receptor 5 (S1PR5) in the Brain by Jiawen Lang (4288540)

Subjects:

Design and Synthesis of Novel PET Radiotracers for Imaging Sphingosine-1-Phosphate Receptor 5 (S1PR5) in the Brain by Jiawen Lang (4288540)

Subjects:

Design and Synthesis of Novel PET Radiotracers for Imaging Sphingosine-1-Phosphate Receptor 5 (S1PR5) in the Brain by Jiawen Lang (4288540)

Subjects:

The effects of pretreatment with fingolimod-phosphate on BMECs in the presence of MS sera. by Hideaki Nishihara (545149)

“…Pretreatment with fingolimod-phosphate resulted in an increase in the claudin-5 protein levels (B) and TEER values (G) and a decrease in the VCAM-1 protein levels (F) in the BMECs, which were upregulated after exposure to the sera from all MS patients, including the RRMS-R, RRMS-S and SPMS patients, compared to that observed in the cells not pretreated with fingolimod-phosphate.…”